Actually, it’s more like David Katz is banging his head against the wall. This is the third time, the investment firm he heads, Matrix Assets Advisors, has written the MedImmune board to urge the little drugmaker to sell itself to a big pharma. So far, though, his pleas have fallen on deaf ears.

His most recent missive comes a week after MedImmune reported revenue results for two high-profile meds disappointed investors, sending its stock down nearly 9 percent and causing one analyst to deem the results “tragic, The Washington Post reports.

Katz wrote the MedImmune board that recent missteps “have served to increase the price gap between the company’s publicly traded valuation and the value that the Company would have to a strategic buyer.” Katz’s firm owns 1.7 million shares, or 0.71 percent of the stock. The Post notes that several analysts believe MedImmune is a prime buyout target.

Not surprisingly, MedImmune blew him off with a canned statement about welcoming shareholder remarks and reviewing his recommendations. So much for valuing shareholder input. But when does that ever really happen, anyway?[tags]Matrix Asset Advisors, MedImmune[/tags]